BACKGROUND: Dosing recommendations for treating childhood tuberculosis (TB) were revised by the World Health Organization, yet so far, pharmacokinetic studies that have evaluated these changes are relatively limited. We evaluated plasma drug concentrations of rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA), and ethambutol (EMB) among children undergoing TB treatment in Tanzania when these dosing recommendations were being implemented. METHODS: At the end of intensive-phase TB therapy, blood was obtained 2 hours after witnessed medication administration to estimate the peak drug concentration (C2h), measured using high-performance liquid chromatography or liquid chromatography-tandem mass spectrometry methods. Differences in median drug concentrations were compared on the basis of the weight-based dosing strategy using the Mann-Whitney U test. Risk factors for low drug concentrations were analyzed using multivariate regression analysis. RESULTS: We enrolled 51 human immunodeficiency virus-negative children (median age, 5.3 years [range, 0.75-14 years]). The median C2hs were below the target range for each TB drug studied. Compared with children who received the "old" dosages, those who received the "revised" WHO dosages had a higher median C2h for RIF (P = .049) and PZA (P = .015) but not for INH (P = .624) or EMB (P = .143); however, these revised dosages did not result in the target range for RIF, INH, and EMB being achieved. A low starting dose was associated with a low C2h for RIF (P = .005) and PZA (P = .005). Malnutrition was associated with a low C2h for RIF (P = .001) and INH (P = .001). CONCLUSIONS: Among this cohort of human immunodeficiency virus-negative Tanzanian children, use of the revised dosing strategy for treating childhood TB did not result in the target drug concentration for RIF, INH, or EMB being reached.
BACKGROUND: Dosing recommendations for treating childhood tuberculosis (TB) were revised by the World Health Organization, yet so far, pharmacokinetic studies that have evaluated these changes are relatively limited. We evaluated plasma drug concentrations of rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA), and ethambutol (EMB) among children undergoing TB treatment in Tanzania when these dosing recommendations were being implemented. METHODS: At the end of intensive-phase TB therapy, blood was obtained 2 hours after witnessed medication administration to estimate the peak drug concentration (C2h), measured using high-performance liquid chromatography or liquid chromatography-tandem mass spectrometry methods. Differences in median drug concentrations were compared on the basis of the weight-based dosing strategy using the Mann-Whitney U test. Risk factors for low drug concentrations were analyzed using multivariate regression analysis. RESULTS: We enrolled 51 human immunodeficiency virus-negative children (median age, 5.3 years [range, 0.75-14 years]). The median C2hs were below the target range for each TB drug studied. Compared with children who received the "old" dosages, those who received the "revised" WHO dosages had a higher median C2h for RIF (P = .049) and PZA (P = .015) but not for INH (P = .624) or EMB (P = .143); however, these revised dosages did not result in the target range for RIF, INH, and EMB being achieved. A low starting dose was associated with a low C2h for RIF (P = .005) and PZA (P = .005). Malnutrition was associated with a low C2h for RIF (P = .001) and INH (P = .001). CONCLUSIONS: Among this cohort of human immunodeficiency virus-negative Tanzanian children, use of the revised dosing strategy for treating childhood TB did not result in the target drug concentration for RIF, INH, or EMB being reached.
Authors: Helen McIlleron; Marianne Willemse; Hendrik Simon Schaaf; Peter John Smith; Peter Roderick Donald Journal: Pediatr Infect Dis J Date: 2011-03 Impact factor: 2.129
Authors: Helen McIlleron; Marianne Willemse; Cedric J Werely; Gregory D Hussey; H Simon Schaaf; Peter J Smith; Peter R Donald Journal: Clin Infect Dis Date: 2009-06-01 Impact factor: 9.079
Authors: Sekai Chideya; Carla A Winston; Charles A Peloquin; William Z Bradford; Philip C Hopewell; Charles D Wells; Arthur L Reingold; Thomas A Kenyon; Themba L Moeti; Jordan W Tappero Journal: Clin Infect Dis Date: 2009-06-15 Impact factor: 9.079
Authors: Hendrik Simon Schaaf; Marianne Willemse; Karien Cilliers; Demetre Labadarios; Johannes Stephanus Maritz; Gregory D Hussey; Helen McIlleron; Peter Smith; Peter Roderick Donald Journal: BMC Med Date: 2009-04-22 Impact factor: 8.775
Authors: Bryan J Vonasek; Kendra K Radtke; Paula Vaz; W Chris Buck; Chishala Chabala; Eric D McCollum; Olivier Marcy; Elizabeth Fitzgerald; Alexander Kondwani; Anthony J Garcia-Prats Journal: Expert Rev Respir Med Date: 2022-02-28 Impact factor: 4.300
Authors: Daniel Van Aartsen; Museveni Justine; Estomih Mduma; Stellah G Mpagama; Mohammad H Alshaer; Charles A Peloquin; Buliga Mujaga; Athanasia Maro; Jean Gratz; Margaret Kosek; Jie Liu; Elizabeth T Rogawski McQuade; Eric R Houpt; Tania A Thomas; Scott K Heysell Journal: Lancet Microbe Date: 2022-04-07
Authors: J W C Alffenaar; S L Stocker; L Davies Forsman; A Garcia-Prats; S K Heysell; R E Aarnoutse; O W Akkerman; A Aleksa; R van Altena; W Arrazola de Oñata; P K Bhavani; N Van't Boveneind-Vrubleuskaya; A C C Carvalho; R Centis; J M Chakaya; D M Cirillo; J G Cho; L D Ambrosio; M P Dalcolmo; P Denti; K Dheda; G J Fox; A C Hesseling; H Y Kim; C U Köser; B J Marais; I Margineanu; A G Märtson; M Munoz Torrico; H M Nataprawira; C W M Ong; R Otto-Knapp; C A Peloquin; D R Silva; R Ruslami; P Santoso; R M Savic; R Singla; E M Svensson; A Skrahina; D van Soolingen; S Srivastava; M Tadolini; S Tiberi; T A Thomas; Z F Udwadia; D H Vu; W Zhang; S G Mpagama; T Schön; G B Migliori Journal: Int J Tuberc Lung Dis Date: 2022-06-01 Impact factor: 3.427
Authors: Claire Szipszky; Daniel Van Aartsen; Sarah Criddle; Prakruti Rao; Isaac Zentner; Museveni Justine; Estomih Mduma; Stellah Mpagama; Mohammad H Al-Shaer; Charles Peloquin; Tania A Thomas; Christopher Vinnard; Scott K Heysell Journal: J Pediatric Infect Dis Soc Date: 2021-03-26 Impact factor: 3.164
Authors: N A H Seneadza; S Antwi; H Yang; A Enimil; A Dompreh; L Wiesner; C A Peloquin; M Lartey; M Lauzardo; A Kwara Journal: Int J Tuberc Lung Dis Date: 2021-01-01 Impact factor: 2.373
Authors: Prakruti S Rao; Christopher C Moore; Amir A Mbonde; Edwin Nuwagira; Patrick Orikiriza; Dan Nyehangane; Mohammad H Al-Shaer; Charles A Peloquin; Jean Gratz; Suporn Pholwat; Rinah Arinaitwe; Yap Boum; Juliet Mwanga-Amumpaire; Eric R Houpt; Leonid Kagan; Scott K Heysell; Conrad Muzoora Journal: Antibiotics (Basel) Date: 2021-06-18
Authors: Luka Verrest; Erica A Wilthagen; Jos H Beijnen; Alwin D R Huitema; Thomas P C Dorlo Journal: Clin Pharmacokinet Date: 2021-06-01 Impact factor: 5.577